1-3 of 3
Megan M. Herr
Close
Sort by
Journal Articles

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy

Megan Melody, Narendranath Epperla, Geoffrey Shouse, Jason Romancik, Pamela Allen, Tamara K. Moyo, Vaishalee Kenkre, Thomas Ollila, Lindsey Fitzgerald, Brian Hess, Kevin David, Megan M. Herr, Oluwatobi Odetola, Adam Lin, Jonathan Moreira, Shuo Ma, Jane N. Winter, Ishan Roy, Deborah Stephens, Alexey Danilov, Nirav N. Shah, Stefan K. Barta, Matthew Cortese, Jonathon B. Cohen, Leo I. Gordon, Reem Karmali
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2327–2331.
https://doi.org/10.1182/bloodadvances.2024012573
Published: 2024
Journal Articles

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

Mehdi Hamadani, Ajay K. Gopal, Marcelo Pasquini, Soyoung Kim, Xianmiao Qiu, Sairah Ahmed, Aleksandr Lazaryan, Vijaya Raj Bhatt, Andrew Daly, Premal Lulla, Stefan Ciurea, Jordan Gauthier, Vaibhav Agrawal, Natalie S. Grover, Lazaros Lekakis, Dipenkumar Modi, Parastoo B. Dahi, Megan M. Herr, P. Connor Johnson, Hamza Hashmi, Peiman Hematti, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2022) 6 (2): 486–494.
https://doi.org/10.1182/bloodadvances.2021005788
Published: 2022
Includes: Supplemental data
Journal Articles

Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes

Clinical Trials & Observations
Megan M. Herr, Sara J. Schonfeld, Graça M. Dores, Eric A. Engels, Margaret A. Tucker, Rochelle E. Curtis, Lindsay M. Morton
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1961–1969.
https://doi.org/10.1182/bloodadvances.2019030924
Published: 2019
Includes: Supplemental data